BAXTER INTERNATIONAL INC
Close on Oct 19, 2026
- Market cap
- $12.94B
- P/E (TTM)
- –
- Dividend yield
- 2.08%
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $2.96B | $0.26 | $0.56 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $2.70B | $-0.03 | $0.36 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $2.97B | $-2.01 | $0.44 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $2.84B | $-0.10 | $0.69 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $2.81B | $0.24 | $0.59 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $2.63B | $0.13 | $0.55 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | Before market open | $2.75B | $-0.95 | $0.58 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $3.85B | $0.27 | $0.80 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted earnings from continuing operations per diluted sharenon-GAAP | full-year | $1.95 to $2.15 | Raised |
| Reported sales growth from continuing operationsGAAP | full-year | 3% to 4% growth | New |
| Organic sales growth from continuing operationsnon-GAAP | full-year | 2% to 3% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Baxter International filed with the SEC
BAXTER APPOINTS JOHN ROGERS CHIEF FINANCIAL OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER ANNOUNCES EARLY TENDER RESULTS AND UPSIZING OF PREVIOUSLY ANNOUNCED CASH TENDER OFFERS
Material agreement · Other events · EX-99.1 to Form 8-K
BAXTER ANNOUNCES PRICING FOR ITS UPSIZED CASH TENDER OFFERS
Material agreement · Other events · EX-99.2 to Form 8-K
BAXTER ANNOUNCES CASH TENDER OFFERS
Other events · EX-99.1 to Form 8-K
BAXTER REPORTS SECOND-QUARTER 2026 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
The following tables present our U.S. and international disaggregated net sales.
Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS FIRST-QUARTER 2026 RESULTS
Results of operations · Other events · EX-99.1 to Form 8-K
International Inc. Spring 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Joel Grade to depart as Baxter CFO; Anita Zielinski named interim CFO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS FOURTH-QUARTER 2025 RESULTS
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Baxter Announces Early Tender Results for 2.600% Senior Notes due 2026 and 1.915% Senior Notes due 2027
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes due 2026 and 1.915% Senior Notes due 2027
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.2 to Form 8-K
BAXTER ANNOUNCES INCREASE IN MAXIMUM TENDER CAP FOR 1.915% SENIOR NOTES DUE 2027
Other events · EX-99.1 to Form 8-K
BAXTER ANNOUNCES TENDER OFFERS FOR 2026 NOTES AND 2027 NOTES
Other events · EX-99 to Form 8-K
BAXTER REPORTS THIRD-QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER REPORTS SECOND-QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER APPOINTS ANDREW HIDER CHIEF EXECUTIVE OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS FIRST-QUARTER 2025 RESULTS
Results of operations · EX-99.1 to Form 8-K
STOCKHOLDER ENGAGEMENT 1 Baxter International Inc. March 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Regulation FD disclosure · EX-99.1 to Form 8-K/A
BAXTER ANNOUNCES CEO RETIREMENT AND APPOINTMENT OF COO
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS THIRD-QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION N o v e m b e r 7 , 2 0 24 1
Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER PROVIDES UPDATE ON NORTH COVE, N.C., FACILITY AND HURRICANE HELENE
Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER ANNOUNCES DEFINITIVE AGREEMENT TO DIVEST ITS VANTIVE KIDNEY CARE SEGMENT TO CARLYLE FOR
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
company’s Kidney Care business), the expected timeframe for completing the pending divestiture, strategic and other potential benefits and costs of the transaction, the company’s ability to minimize or eliminate those costs and other
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
BAXTER REPORTS SECOND-QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER REPORTS FIRST-QUARTER 2024 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER REPORTS THIRD-QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER APPOINTS JOEL GRADE CHIEF FINANCIAL OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS SECOND-QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
STOCKHOLDER ENGAGEMENT 1 Baxter International Inc. July 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to
Material agreement · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Jay Saccaro to depart as CFO; Brian Stevens appointed interim CFO
Material agreement · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
BAXTER REPORTS FIRST-QUARTER 2023 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS
Results of operations · EX-99.1 to Form 8-K
BAXTER ANNOUNCES STRATEGIC ACTIONS TO ENHANCE OPERATIONAL EFFECTIVENESS, ACCELERATE INNOVATION FOR PATIENTS AND DRIVE VALUE FOR SHAREHOLDERS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BAXTER REPORTS THIRD-QUARTER 2022 RESULTS
Results of operations · EX-99.1 to Form 8-K